Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 505

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 505
---
 Ex-U.S.Territory and (b) to use the Licensed Trademark in connection with the commercialization of the Licensed Products in the Romeg Ex-U.S.Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. As consideration for the license under the Romeg License Agreement, the Company agreed to pay Romeg (1) an up-frontlicense fee of $ 2.0million, (2) upon the Company’s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $ 13.0million, (3) certain royalties in the mid-singledigit percentage based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the Romeg U.S. Territory Royalty Term, with a quarterly minimum royalty of $ 150,000, and (4) pursuant to the amendment thereto, (a) certain royalties at rates in the low-singledigit percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg Ex-U.S.Territory during the Romeg Ex-U.S.Territory Royalty Term and (b) a one-time, non-refundable, non-creditablepayment of $ 700,000. Pursuant to the amendment agreement, we also transferred to Romeg 22,267shares of our Common Stock. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $ 5.7million, which is comprised of the upfront license fee of $ 2.0million and deferred consideration of $ 3.7million that is the present value of the future minimum royalty payments and immaterial transaction costs. During the years ended December 31, 2024 and 2023, the Company made royalty payments in the amount of $ 0.6million and $ 0.3million, respectively. Nocontingent consideration was recognized as a liability or included in the fair value of the assets as of December 31, 2024 or December 31, 2023. ELYXYB Acquisition In February 2023, the Company entered into an asset purchase agreement (the “ELYXYB APA”) with BioDelivery Sciences International, Inc. (“BDSI”) and Collegium Pharmaceutical, Inc. (“Collegium”, and together with BDSI, the “Sellers”)